TEAM

Paul Halpern, JD (CEO) is the Chief Investment Officer at Versa Capital Management, LLC,  private equity firm with over $1.25 billion under contract.

Scott Dessain, MD, PhD (CSO) is a medical oncologist and immunologist who developed the OCMS technology in his laboratory at the  Lankenau Institute for Medical Research. He co-founded Immunome, Inc. (NASDAQ: IMNM).

Thomas Halpern, (COO) is an expert in project management. As a Marine Captain, he oversaw the movements of over 1,000 Marines and their equipment to 12 sites in 7 Middle Eastern countries.

Rama Devudu Puligedda, PhD (Director of Immunology Research) is an immunologist with over 18 years of experience  and co-inventor of the OCMS technology.  Dr. Puligedda is responsible for the discovery of numerous critical antibodies, including the new international potency standard for inactivated poliovirus vaccines (IPV).

Onne Ganel, MBA, (Business Development) has spent two decades in the healthcare technology field and led acquisitions in excess of $500m in total value on behalf of Fortune 500 companies, and commercializing technologies across the healthcare spectrum